Intelligent Bio Solutions (NASDAQ: INBS) launches multi-site 510(k) codeine drug screening study
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Intelligent Bio Solutions Inc. is starting a multi-site Method Comparison Study to support an FDA 510(k) submission for U.S. clearance of its Intelligent Fingerprinting Drug Screening System for the opiate codeine. The company is working with CenExel Clinical Research to test the system’s accuracy when used by typical workplace screening staff.
The study will enroll 135 donor participants and use nine operator participants to mirror real-world employment and safety-sensitive settings. Key metrics such as sensitivity, specificity, and overall accuracy will be confirmed using LC-MS/MS, and enrollment and data collection are expected to finish by the end of July 2026, with results included in the company’s 510(k) package.
Positive
- None.
Negative
- None.
8-K Event Classification
2 items: 7.01, 9.01
2 items
Item 7.01
Regulation FD Disclosure
Disclosure
Material non-public information disclosed under Regulation Fair Disclosure, often investor presentations or guidance.
Item 9.01
Financial Statements and Exhibits
Exhibits
Financial statements, pro forma financial information, and exhibit attachments filed with this report.
Key Figures
Donor participants: 135 participants
Operator participants: 9 operators
Study completion target: End of July 2026
3 metrics
Donor participants
135 participants
Enrolled and randomized into dosing groups for Method Comparison Study
Operator participants
9 operators
Typical workplace drug screening personnel using the system
Study completion target
End of July 2026
Expected completion of enrollment and data collection
Key Terms
FDA 510(k), Method Comparison Study, sensitivity, specificity, +2 more
6 terms
FDA 510(k) regulatory
"to support its FDA 510(k) submission for U.S. market clearance"
A FDA 510(k) is a premarket notification a medical device maker files to show a new device is similar enough to an already approved device that it can be marketed without a lengthy review. For investors it matters because a cleared 510(k) offers a faster, lower-cost path to sell a product and reduces regulatory uncertainty—think of it like proving you’re using an approved recipe rather than inventing a brand-new one.
Method Comparison Study technical
"announced the initiation of a multi-site Method Comparison Study"
sensitivity technical
"The study will assess key performance metrics, including the system’s sensitivity, specificity"
specificity technical
"key performance metrics, including the system’s sensitivity, specificity, and overall accuracy"
Specificity measures how well a diagnostic test or screening correctly identifies people who do not have a condition — the percentage of healthy cases the test labels as negative. Think of it as a smoke alarm that stays quiet when there’s no fire; high specificity means fewer false alarms. For investors, specificity affects regulatory approval, clinical adoption, follow-up costs, and the perceived reliability and market potential of medical products.
LC-MS/MS technical
"Results will be independently confirmed via liquid chromatography-tandem mass spectrometry (“LC-MS/MS”)"
LC‑MS/MS is a laboratory technique that first separates a mixture of chemicals in a liquid, then identifies and measures each component with very high sensitivity—think of sorting mixed mail and then scanning barcodes to know exactly what’s inside. It matters to investors because it produces precise, reliable data used in drug development, safety testing, diagnostics and product quality control, and those results influence regulatory approvals, market access and commercial claims that can affect a company’s value.
ICH GCP regulatory
"conducted across multiple sites in accordance with ICH GCP ... Guidelines"
An international set of standards that describes how clinical trials should be designed, conducted, recorded and reported to protect people taking part and to ensure the data are reliable. Think of it like a safety checklist and blueprint for medical studies: when companies follow it, regulators and investors can trust the results; when they don’t, trials can be delayed, rejected or lead to legal and financial risks that affect a company’s value.
FAQ
What did Intelligent Bio Solutions (INBS) announce in this 8-K filing?
Intelligent Bio Solutions announced it has begun a multi-site Method Comparison Study to support an FDA 510(k) submission for U.S. clearance of its Intelligent Fingerprinting Drug Screening System for codeine, aiming to validate accuracy and workplace performance in real-world screening environments.
What is the purpose of INBS’s Method Comparison Study for the fingerprint drug test?
The study is designed to evaluate the Intelligent Fingerprinting Drug Screening System’s sensitivity, specificity, and overall accuracy when operated by typical workplace personnel, generating clinical evidence required for the FDA 510(k) submission and demonstrating effective use in real employment and safety-critical settings.
How is Intelligent Bio Solutions (INBS) structuring its new drug screening study?
The study plans to enroll 135 donor participants randomized into dosing groups with U.S.-representative demographics, and involve nine operator participants who mirror workplace drug screening staff, allowing performance evaluation across multiple clinical sites using fingerprint sweat specimens for codeine detection.
When does INBS expect to complete enrollment and data collection for the study?
The company expects to complete enrollment and data collection by the end of July 2026. Results from this Method Comparison Study will be incorporated into Intelligent Bio Solutions’ FDA 510(k) submission package alongside data from a previously announced clinical cut-off study started in January 2026.
How will INBS confirm the accuracy of its Intelligent Fingerprinting Drug Screening System?
Accuracy will be assessed using key metrics such as sensitivity, specificity, and overall accuracy, with results independently confirmed through liquid chromatography-tandem mass spectrometry (LC-MS/MS), which is described as the gold standard method for confirming drug detection in clinical and workplace testing contexts.
Why is user performance important in INBS’s FDA 510(k) submission?
User performance is a key component of the submission because the study aims to show that typical occupational health, HR, and workplace safety personnel can operate the system accurately without specialized laboratory training, supporting the company’s emphasis on ease of use in workplace drug screening markets.